Skip to main content

CXCR2+ Granulocytic Myeloid-Derived Suppressor Cells with the Development of CCA: A Possible Target for Intervention

2020 Year in Review - Cholangiocarcinoma - Cholangiocarcinoma

Preclinical data implicate the ELR+ chemokine/CXCR2 axes in the pathogenesis of CCA, warranting further studies to define its role in CCA.

The prognosis of CCA remains poor, which may be partly attributable to high rates of unresectability, recurrence, and suboptimal response to standard chemotherapy, highlighting the need for novel systemic therapies. However, to further these efforts, effective preclinical models for identifying and testing new targeted or immune-based therapies are needed. At the American Society of Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium, a spontaneous murine model of CCA was used to better understand the biology underlying the pathogenesis of CCA.

By histology and immunohistochemistry (IHC) staining with digital quantification performed on archival human CCA, significantly higher levels of CD15+CXCR2+ granulocytic myeloid-derived suppressor cells (G-MDSC) were found compared with adjacent normal liver (P = .0019). In addition, the CXCR2 ligand, CXCL5, was significantly elevated in CCA tumors compared with adjacent normal liver (P =.0065). These data implicate the ELR+ chemokine/CXCR2 axes in the pathogenesis of CCA to mobilize and recruit immunosuppressive G-MDSC to the tumor microenvironment.

To better understand the biology of CCA tumors, histologic and gene-expression studies were conducted in hepatic tumors grown in the spontaneous murine CCA model, which is characterized by hepatic KRAS activation and loss of p53, and normal livers from littermate controls. In addition, flow cytometric analysis was performed on bone marrow, spleen, peripheral blood from hepatic tumors, as well as controls.

In spontaneous CCA mice, quantitative real-time polymerase chain reaction tests showed a significant increase in expression of granulocyte colony-stimulating factor (CSF), CSF1, CXCL1, CXCL2, and CXCL5 (P = .0001) in the hepatic tumors compared with normal livers. Consistent with observations in the primary human CCA, flow cytometric analysis of hepatic tumors showed significantly elevated levels of CD45-positive leukocytes comprised of immunosuppressive G-MDSC compared with normal littermate controls (P = .0007). Also, a higher proportion of granulocytes in the bone marrow and blood were observed in spontaneous CCA mice compared with normal littermate controls.

These data suggest that the ELR+ chemokine/CXCR2 axes may potentially be involved in CCA pathogenesis and supports the utility of the spontaneous murine CCA model in preclinical evaluations of potential therapeutic interventions targeting this pathway.

Source: Ullman NA, et al. J Clin Oncol. 2020;38(4_suppl). Abstract 565.

 

Related Items
Key Advances in the Treatment of Patients with BTC in 2023: New Targeted Therapies, Potential Biomarkers, and Combination Strategies
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
KEYNOTE-966: Pembrolizumab Combined With GemCis Versus GemCis Alone in Patients With BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Post-hoc Analysis of the ABC-01, -02, and -03 Trials in Patients With Advanced eCCA
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Efficacy and Safety of Tinengotinib in Patients With Advanced Refractory/Relapsed CCA Who Previously Received an FGFR Inhibitor
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
KLF5 Inhibition Reduces Tumor Growth and Sensitizes to Chemotherapy-Induced Cell Death in Experimental Models of CCA
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Phase 2 Trial of SHR-1316 Plus IBI310 in Patients With Advanced iCCA After Inadequate Response to First-Line Therapy
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Examination of Patients With CCA Treated With Novel Targeted Therapies After Extended Molecular Profiling on Liquid Biopsies
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
Phase 2 Component of the BEER-BTC Study: Comparing Bevacizumab Plus Erlotinib Maintenance Versus Observation in Patients With Advanced BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
The DEBATE Trial: Neoadjuvant Durvalumab Plus GemCis Versus GemCis Alone for Patients With Localized BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma
The Phase 2 ADJUBIL Study of Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC
2023 Year in Review - Cholangiocarcinoma published on December 31, 2023 in Cholangiocarcinoma